2023-08-15 22:21:10
First-half results…Guangdong-Dongguk-China flight, Jeil-Ildong-Ilyang sales slowdown
The blue light was turned on as domestic pharmaceutical companies generally marched high in the first half.
According to the results of the first half of the year submitted to the Financial Supervisory Service, sales of 34 KOSPI-Kostak domestic pharmaceuticals were 5,576.6 billion won, an 8% increase of 374.9 billion won from 5,201.7 billion won in the same period last year.
In addition, operating profit increased by 62% to 310.1 billion won, an increase of 118.8 billion won from 191.3 billion won in the same period last year. Net profit also increased by 76% to KRW 222.9 billion from KRW 126.5 billion in the same period last year.
However, by company, unlike pharmaceutical companies such as Kwangdong Pharm, Dongkuk Pharm, and Choongwae Pharm, which are running net growth, Jeil Pharm, Ildong Pharm, and Il-yang Pharm have created an atmosphere of slowing down.
First, in terms of sales, Kwangdong Pharmaceutical recorded 732.3 billion won, a 9% increase from 674.1 billion won in the same period last year, showing the highest sales among these pharmaceutical companies. Jeil Pharma Holdings, the holding company, posted 406.3 billion won, down slightly from 408.3 billion won in the same period last year.
On the other hand, Dongkuk Pharm posted sales of 366.7 billion won, up 9% from 335.5 billion won in the same period last year, and JW Pharmaceutical also achieved 354.9 billion won, up 12% from 317.2 billion won in the same period last year, drawing an upward curve.
In addition, Ildong Holdings, the holding company, recorded 319.8 billion won, -6% year-on-year, and Ildong Pharmaceutical recorded 299.4 billion won, -7% year-on-year. 10% growth showed good performance.
In the case of pharmaceutical companies worth 100 billion won, Ilyang Pharm recorded 165.7 billion won, down 2% from the previous year, Hugel 145.9 billion won, 16%, Samjin 143.1 billion won, 12%, SK Biopharmaceuticals 137.8 billion won, 46%, Pharma Research 122.2 billion won, 29%, Pharmaceutical companies excluding Ilyang made a high growth rate, with Anguk Pharm growing 20% with 114.1 billion won, Hana Pharm 9% with 111.5 billion won, and Daehan New Pharm 9% with 104.4 billion won.
JW Life Science 12%, Alico Pharmaceutical 20%, Daehan Pharm 9%, Medytox 6%, Samil 4%, Bukwang 1%, Myungmoon 11%, Humedix 29%, HanAll Bio 40% , Yuyu -2%, JW Shinyak 8%, Dongsung -1%, JW Holdings -9%, Hankook Pharma 11%, Shinil 3%, Ilsung 35%, BC World 10%, showing different growth rates.
Operating profit of Hugel KRW 46.6 billion, Pharma Research KRW 44.4 billion, Sino-foreign KRW 44.2 billion
In terms of operating profit, Hugel posted a record high of 46.6 billion won. However, it was the same as the previous year. Pharma Research ranked 44.4 billion won, JW Pharmaceutical 44.2 billion won, Dongkuk 32.2 billion won, and Huons 29.1 billion won.
In terms of increase and decrease rate, Hanall Biopharma recorded the highest with 6993%, followed by BC World Pharm 413%, Yuyu 134%, JW Heavy Industries 81%, Humedix 73%, Anguk 54%, Guangdong 44%, Alico 40%. business was good Jeil Pharma Holdings, Jeil Pharmaceutical, and Dongsung Pharmaceutical turned to profit, forming a new atmosphere.
In contrast, Ildong Holdings, Ildong Pharmaceutical, SK Biopharmaceuticals, Bukwang, and Ilsung Pharmaceutical were still in the red. Ildong Holdings paid 10.2 billion won in consolation money and Ildong Pharmaceutical paid 9.6 billion won for voluntary retirement that lasted until June.
Samil 2200%, BC World 1158% net profit growth rate ‘giyeom’…everyone continues to lose
In terms of net profit, Hugel recorded 38.4 billion won, leaving other pharmaceutical companies behind. JW Pharmaceutical was followed with 33.7 billion won, Pharma Research 33.5 billion won, Huons 28.7 billion won, Dongkuk 26.4 billion won, Guangdong 24 billion won, Jeil Pharma Holdings 18.3 billion won, Daewon 17.5 billion won, Daehan Pharmaceutical 14.7 billion won, Medytox 14.5 billion won, Humedix 14.4 billion won. , followed by Ilsung New Drug with 14.3 billion won.
In terms of growth rate, Samil Pharm recorded the highest growth at 2200%, followed by BC World Pharm 1158%, JW Jungwae 166%, Guangdong 97%, Huons 77%, Pharma Research 71%, and JW Holdings 65%. Again, Jeil Pharma Holdings, Jeil Pharm, and Hanall Bio turned to the black, while Myungmoon Pharm, JW New Drug, and Korea Pharma turned to the red. Ildong Holdings, Ildong, SK Biopharm, Bukwang, Yuyu, and Dongsung continued to lose money.
© News The Voice Healthcare Unauthorized reproduction and redistribution prohibited
1692142365
#domestic #pharmaceuticals.. #sales #operating #profit #net #profit #growth #blue #light
